 This is an investigator-initiated, multi-center, prospective observational phase II trial evaluating MRI to detect prostate cancer progression in patients with low risk prostate cancer on Active Surveillance. The two centers involved will be the Yale-New Haven Hospital Smilow Cancer Center Yale and the VA Connecticut Healthcare System VACT. The Yale School of Medicine will serve as the central data-coordinating center for this study. 